Amarin Corporation plc Stock price

Equities

AMRN

US0231112063

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
0.8908 USD +0.18% Intraday chart for Amarin Corporation plc +3.40% +2.39%
Sales 2024 * 224M Sales 2025 * 233M Capitalization 366M
Net income 2024 * -60M Net income 2025 * -52M EV / Sales 2024 * 0.66 x
Net cash position 2024 * 218M Net cash position 2025 * 188M EV / Sales 2025 * 0.77 x
P/E ratio 2024 *
-5.98 x
P/E ratio 2025 *
-6.66 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 92.73%
More Fundamentals * Assessed data
Dynamic Chart
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Ease Wednesday MT
European Equities Traded in the US as American Depositary Receipts Start Week Slightly Lower in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Decline Tuesday MT
European Equities Traded in the US as American Depositary Receipts Rise Monday Afternoon MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading But End Week Flat MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading MT
Transcript : Amarin Corporation plc, Q4 2023 Earnings Call, Feb 29, 2024
Amarin Corporation plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Amarin Corporation plc Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (AMRN) AMARIN CORPORATION Posts Q4 Revenue $74.7M, vs. Street Est of $71.1M MT
Earnings Flash (AMRN) AMARIN CORPORATION Posts Q4 EPS $-0.01, vs. Street Est of $-0.03 MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise Modestly in Tuesday Trading MT
More news
1 day+0.18%
1 week+3.40%
Current month-16.75%
1 month-32.52%
3 months-0.99%
6 months-2.10%
Current year+2.39%
More quotes
1 week
0.83
Extreme 0.8339
0.92
1 month
0.80
Extreme 0.8015
1.07
Current year
0.80
Extreme 0.8015
1.37
1 year
0.65
Extreme 0.651
1.55
3 years
0.65
Extreme 0.651
6.58
5 years
0.65
Extreme 0.651
26.12
10 years
0.65
Extreme 0.651
26.12
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 23-07-17
Director of Finance/CFO 52 22-06-19
Compliance Officer 55 Nov. 14
Members of the board TitleAgeSince
Director/Board Member 45 23-02-27
Chairman 49 23-02-27
Director/Board Member 66 23-02-27
More insiders
Date Price Change Volume
24-03-28 0.8908 +0.18% 1,155,617
24-03-27 0.8892 +2.68% 1,256,561
24-03-26 0.866 +2.62% 592,820
24-03-25 0.8439 -1.84% 854,020
24-03-22 0.8597 -0.21% 674,393

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
4
Last Close Price
0.8908 USD
Average target price
1.083 USD
Spread / Average Target
+21.61%
Consensus
  1. Stock
  2. Equities
  3. Stock Amarin Corporation plc - Nasdaq